Author

Luis Fernández-Salazar

EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

HUMAN INTESTINAL CD103+SIRP-ALPHA+ CONVENTIONAL DENDRITIC CELLS FROM PATIENTS WITH CROHN´S DISEASE PRIME IL-17+ T-CELLS
HUMAN INTESTINAL CD103+SIRP-ALPHA+ CONVENTIONAL DENDRITIC CELLS FROM PATIENTS WITH CROHN´S DISEASE PRIME IL-17+ T-CELLS

Luis Fernández-Salazar  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Luis Fernández-Salazar  et al.

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

UNRAVELLING THE HUMAN GASTRIC IMMUNE SYSTEM BY SPECTRAL CYTOMETRY CONFIRMS THE PRESENCE OF INTER-INDIVIDUAL VARIABILITY AND LACK OF REGIONAL VARIATION WITHIN THE GASTRIC MUCOSA
UNRAVELLING THE HUMAN GASTRIC IMMUNE SYSTEM BY SPECTRAL CYTOMETRY CONFIRMS THE PRESENCE OF INTER-INDIVIDUAL VARIABILITY AND LACK OF REGIONAL VARIATION WITHIN THE GASTRIC MUCOSA

Luis Fernández-Salazar  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Luis Fernández-Salazar  et al.

PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY
PROTEOMIC PROFILE OF SERUM AND URINE IN NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE: NEW APPROACH FOR BIOMARKER DISCOVERY

Luis Fernández-Salazar  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Luis Fernández-Salazar  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Luis Fernández-Salazar  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 6,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Luis Fernández-Salazar  et al.

EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY IN 5,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

Luis Fernández-Salazar  et al.

COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
COMPARISON OF THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION REGIMENS BETWEEN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

ROLE OF THE PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF THE PROTON PUMP INHIBITORS IN HELICOBACTER PYLORI ERADICATION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Fernández-Salazar  et al.

Item 1 - 20 / 21
1
2